Skip to main content
OpenTrials
Completed

NCT Number: NCT02848144

Pediatric Immune Response to Infectious Shock

Infectious shocks are associated with high mortality rates (20-40%). Anti-inflammatory strategies based on the postulate that mortality related to sepsis is mainly due to an overwhelming pro-inflammatory immune response have failed. Some patients surviving this initial phase can develop immune dysfunctions because the compensatory mechanisms become deleterious when they persist over time. The persistence of immunosuppression at day 3 or 5 is independently associated with more nosocomial infections and higher mortality rate. The clinical and laboratory evidence for sepsis induced immunosuppression have been recently reviewed by Hotchkiss et al. Apoptosis-induced depletion of immune effector and blood studies from septic patients showed decreased production of pro-inflammatory cytokines, decreased HLA-DR expression, increased percentage of regulatory T cells, and increased production of programmed cell death (PD)-1. Some small positive phase 2 trials of biomarker guided immune enhancing agents granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon γ (IFN γ) have been reported.

There are insufficient data showing that such an immunosuppression exists in children. Only one study performed in children with organ dysfunctions admitted to pediatric intensive care unit (PICU), showed that 34% of them developed immunosuppression. This study was performed on a heterogeneous population and immunological analyses were limited. Therefore, there is a crucial need of studies on septic patients with matched controls to provide more evidence that the same paradigm exists in children. The collaboration of laboratories with a high level of experience in this domain, and a clinical unit with a high potential of recruitment of children with severe infectious shock should allow us to perform the first prospective study specifically done in children with infectious shock.

The main hypothesis is that children with severe infectious shock developed sepsis-induced immunosuppression as shown in adults. This will be assessed by the expression of HLA-DR on monocytes' surface. We make the hypothesis that children who become immunosuppressed are more prone to develop secondary nosocomial infectious and stayed longer in PICU and in hospital.

Children aged from 1 month to 17 years, admitted to PICU at HFME Lyon-Bron are eligible if they have the criteria for severe sepsis or septic shock, defined by the "Surviving Sepsis Campaign 2012" or those of Toxic Shock Syndrome (TSS) (definitions of CDC - Center for Disease Control). An information leaflet will be issued to parents and children / adolescents and they will be informed of their right to object to the search. Are provided as part of this research:

* Immunological measures (mHLA -DR) in three stages: in the first 48 hours, between D3/5 and D7/9. The volume of collected blood will not exceed 2.4 ml / kg. * The collection of nosocomial infections and status at D30 A control group of patients hospitalized for surgery without sepsis or toxic shock criteria will be recruited in the same hospital by ICU investigators and matched for age. Similarly controls will be given oral and written information and they will have the opportunity to deny inclusion. They will have the same exams as the first group of patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospices Civils de Lyon

Lyon, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Infectious shock group:

  • Children aged from 1 month to <18 years
  • Diagnosis of severe infectious shock at PICU or within the first 24 hours following PICU admission: severe sepsis or septic shock, defined by Surviving Sepsis Campaign 2012, or Toxic Shock Syndrome, defined by CDC criteria.

Inclusion criteria

Control group:

  • Healthy children aged matched to cases
  • Hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage)
  • Without any criteria of infection.

Exclusion criteria

(both groups):

  • Chronic inflammatory disease;
  • Immunodeficiency;
  • Long-term corticosteroids;
  • Ongoing immunosuppressive treatment;
  • Transplanted patients;
  • Tumors, hematological diseases;
  • No health insurance coverage;
  • Refusal to participate (from parents and/or patient) or inability to understand information.

Treatment and study plan

Blood Samples

Other

Collection of nosocomial infections

Other

Primary outcomes

  1. proportion of patients with a mHLA-DR level <30%

    Time frame: up to Day 9

    mHLA-DR is measured by flow cytometry

  2. proportion of patients with a mHLA-DR level significantly lower than healthy children.

    Time frame: in the pre-operative period

    mHLA-DR is measured by flow cytometry

Secondary outcomes

  1. total lymphocytes

    Time frame: Day 1

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  2. total lymphocytes

    Time frame: between Day 3 and day 5

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  3. total lymphocytes

    Time frame: between Day 7 and day 9

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  4. levels of CD4+

    Time frame: Day 1

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  5. levels of CD4+

    Time frame: between Day 3 and day 5

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  6. levels of CD4+

    Time frame: between Day 7 and day 9

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  7. levels of CD25+

    Time frame: day 1

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  8. levels of CD25+

    Time frame: between Day 3 and day 5

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  9. levels of CD25+

    Time frame: between Day 7 and day 9

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  10. levels of T lymphocytes (Treg)

    Time frame: Day 1

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  11. levels of T lymphocytes (Treg)

    Time frame: between Day 3 and day 5

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  12. levels of T lymphocytes (Treg)

    Time frame: between Day 7 and day 9

    From the whole blood samples, each lymphocytes sub-populations are determined by flow-cytometry with addition of specific monoclonal antibodies

  13. dosage of cytokines

    Time frame: Day 1

  14. dosage of cytokines

    Time frame: between Day 3 and day 5

  15. dosage of cytokines

    Time frame: between Day 7 and day 9

  16. Number of nosocomial infections

    Time frame: up to Day 30

  17. Type of nosocomial infections

    Time frame: up to Day 30

    bacteremia, ventilator-associated pneumonia, urinary tract infection, other sites.

  18. Mortality

    Time frame: up to Day 30

  19. Length of vasoactive treatments

    Time frame: up to Day 30

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: PedIRIS

Important dates

Study start
2014
Primary completion
2018
Study completion
2018
First posted
Jul 28, 2016
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.